BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Drug Development

  Ocugen Ends Week on Low as FDA Rejects Covaxin EUA for Kids

  The FDA turned down Ocugen’s Emergency Use Authorization request for Covaxin in children 2 to 18, which the company is co-developing with India’s Bharat Biotech.

  March 4, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Moderna and Pfizer are Well-Positioned to Take mRNA into the Future

  As COVID-19 cases fall in the wake of the latest surge from the Omicron variant, the question on the minds of many is, what comes next for these Pfizer and Moderna?

  March 4, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Career Advice

  What You Can do With a Life Science Degree

  A life science degree can provide various academic and professional opportunities to you. Here’s an overview of what you can do with a life science degree.

  March 4, 2022

   · 

  4 min read

   · 

  Karen Walpole
• 

  Policy

  Australia’s Japanese Encephalitis Cases Signal New Climate Change Warning

  Several cases of Japanese encephalitis have been confirmed in Australia and may have spread from pigs to humans, although it can also spread from horses.

  March 4, 2022

   · 

  2 min read

   · 

  Mark Terry
• 

  Drug Development

  Clinical Catch-Up: Covaxin, Celyad Hold, CRISPR’s Next Step

  The biopharma industry ended February and began March with plenty of clinical trial news. BioSpace shares the highlights.

  March 4, 2022

   · 

  8 min read

   · 

  Mark Terry
• 

  Deals

  Illumina’s Acquisition of GRAIL Faces Another Roadblock

  The European Commission has provided an update that it remains unconvinced by the merger, which spells bad news for Illumina.

  March 4, 2022

   · 

  2 min read

   · 

  Hayley Shasteen
• 

  Policy

  Majority of Funds from New Sackler Family Deal will go to Treatment

  Members of the Sackler family will dedicate at least $5.5 billion plus 100% of the debtors’ assets to opioid abatement and victims.

  March 4, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  COVID-19 and the Penis, Misinformation Investigation and the Question of Masks

  A study in monkeys found the virus infects the male genital tissues. For that and more COVID-19 news, continue reading.

  March 4, 2022

   · 

  5 min read

   · 

  Mark Terry
• 

  Drug Development

  COVID-19 Tests Spark New At-Home Revolution for Genetics, STI Versions

  Although at-home testing for COVID-19 has been dismal, the revolution in at-home testing has inspired personal tests for several other illnesses.

  March 4, 2022

   · 

  3 min read

   · 

  Hannah Chudleigh
• 

  Drug Development

  Prasad Out at vTv after Just Six Months on the Job

  Six months into the job, Chief Executive Officer Deepa Prasad left vTv Therapeutics. Not long ago, the former CEO dramatically slashed its workforce to ensure funding for its lead diabetes asset.

  March 4, 2022

   · 

  2 min read

   · 

  Alex Keown